On April 13, 2026, Revolution Medicines presented transformative data from its Phase III RASolute 302 study. According to the report, the company’s oral inhibitor, daraxonrasib, nearly doubles the chances of survival in patients with metastatic forms of the disease.
This result is particularly promising against the backdrop of the grim reality where the survival rate for metastatic cases of the disease stands at only 3%. Given this critical context, the success of daraxonrasib in second-line therapy signals the establishment of a new clinical standard.
Historical Context in PDAC Treatment
In the field of pancreatic cancer treatment, therapeutic progress has been minimal since 1997, when gemcitabine was approved. The FOLFIRINOX and nab-paclitaxel regimens introduced in subsequent decades resulted in only a negligible increase in the survival rate. Furthermore, the KRAS G12C inhibitors successful in lung cancer therapy proved ineffective against PDAC due to the disease’s specific mutational profile.
Amidst this prolonged stagnation, daraxonrasib is the first oral KRAS-targeted therapy to achieve such large-scale success in a Phase III study. Beyond its high monotherapeutic activity, the drug is organically compatible with innovative methods such as stromal modulators and ADC technologies.
A New Strategy for Defeating KRAS Mutations
In 90-95% of pancreatic adenocarcinoma cases, the development of the disease is linked to KRAS mutations. These genetic changes drive aggressive tumor growth through the continuous activation of MAPK and PI3K signaling pathways. While early therapeutic agents were directed toward the protein’s inactive, GDP-bound state, daraxonrasib relies on a completely different mechanism. The drug selectively blocks the active, GTP-bound RAS(ON) conformation.
This innovative mechanism effectively hinders the binding of effector proteins and the transmission of oncogenic signals. Moreover, to reduce toxicity to a minimum, the drug avoids acting on wild-type RAS proteins as much as possible.
The efficacy of the therapy was already highlighted by early studies conducted in 2024-2025. Observation of more than 120 patients confirmed the drug’s high activity and its unique ability to penetrate the central nervous system. It was these promising findings that created a solid foundation for the transition to the large-scale Phase III project.
Study Details
RASolute 302 was a global, multicenter, randomized Phase III study conducted in the world’s leading medical centers. The cohort of 441 patients was composed of individuals who experienced a recurrence of the disease despite systemic treatment. Mandatory conditions for participation included biopsy-confirmed KRAS mutations and adequate ECOG status scores.
To protect the objectivity of the data, patient stratification was carried out according to regional affiliation, prior therapeutic regimens, and specific variants of the KRAS mutation. Based on this process, participants were divided into two identical groups: in one case, therapy involved daraxonrasib monotherapy, while in the other, a standard chemotherapy course selected by the researcher.
The statistical power of the study was designed to detect a 30% difference in the overall survival rate. The primary endpoints of the project were overall survival (OS) and progression-free survival (PFS). Secondary parameters included a complex analysis of the objective response rate (ORR), quality of life, and safety profile, while the impartiality of the process was controlled by an Independent Data Monitoring Committee (IDMC).
Study Results
Analysis of the study results confirmed the efficacy of daraxonrasib across all primary parameters. Particularly significant is the overall survival (OS) rate, the median of which in the daraxonrasib group was 13.2 months. This parameter is nearly double the result of the chemotherapy group (6.7 months). Statistically, this difference implies a 49% reduction in the risk of mortality.
A similar positive dynamic was identified in progression-free survival (PFS): it amounted to 5.6 months in the daraxonrasib group, which is double the chemotherapy rate (2.5 months). The drug’s objective response rate (ORR) was 28% (including four complete remissions), the median duration of response was 9.2 months, and the disease control rate (DCR) exceeded 70%.
According to subgroup analysis, the therapeutic benefit is stable across all major categories, including groups with the KRAS G12D mutation (40% of cases), liver metastases, and patients over 65 years of age. The absence of data heterogeneity points to the drug’s broad clinical potential.
Side Effects
The safety profile analysis confirmed that the side effects caused by daraxonrasib are clinically manageable. Although side effects were noted in 95% of patients, grade 3 or higher complications were recorded in only 25%, which is significantly less than the chemotherapy group rate (40%).
Among the common symptoms, diarrhea, nausea, fatigue, and rash predominated. Laboratorially, a transient increase in lipase levels and anemia were revealed, though this had no impact on the treatment process. Despite serious side effects (30%), only 8% of patients required discontinuation of therapy.
Notably, no treatment-related fatal cases were recorded. Furthermore, the time to deterioration in quality of life proved to be significantly longer in the daraxonrasib group, indicating the drug’s favorable therapeutic index.
Future Stages
Based on the Breakthrough Therapy status granted in 2025, daraxonrasib will move into priority review mode by the FDA. The company plans to present the full data from the study at the ESMO and ASCO congresses and to file applications with regulatory bodies (FDA, EMA) by the end of the current year. However, the development of the drug is not limited to this alone. Parallel studies are actively examining the efficacy of daraxonrasib in combination with first-line chemotherapy, as well as in the treatment of lung and colorectal cancers.
Despite positive expectations, several significant challenges remain before practical implementation. Foremost among them is the wide implementation of KRAS genetic testing (NGS), which ensures proper patient selection. Additionally, the future strategy envisions combating acquired resistance and optimizing combined therapeutic schemes. These steps serve to maximize the clinical benefit of the drug.
Source: CNBC
